SEARCH

SEARCH BY CITATION

References

  • 1
    Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:10541058.MEDLINE
  • 2
    Katlama C, Duvivier C, Chouquet C, Autran B, Garcelain G, De Sa M, Zagury L, et al. ILSTIM (ANRS 082)—A randomized comparative open-label study of interleukin-2 in patients with CD4 < 200/mm3 despite effective HAART [Abstract #543]. In: 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000, p. 177.
  • 3
    Uberti-Foppa C, De Bona A, Morsica G, Guffanti M, Gianotti N, Boeri E, Lazzarin A. Recombinant interleukin-2 for treatment of HIV reduces hepatitis C viral load in coinfected patients. AIDS 1999; 13:140141.MEDLINE
  • 4
    Gianotti N, Uberti-Foppa C, Boeri E, Marinelli M, Tambussi G, Finazzi R, Lazzarin A. Hepatitis B surface antigen clearance and appearance of antibodies against hepatitis B surface antigen after treatment with recombinant interleukin 2 in a human immunodeficiency virus-infected patient. Hepatology 2000; 32:14091410.MEDLINE
  • 5
    Hengge UR, Roggendorf M, Goos M. Lack of significant viral load alterations of hepatitis B virus and hepatitis C virus during treatment with IL-2 and highly active antiretroviral therapy. AIDS 2000; 14:26172619.MEDLINE